Free weekly newsletter

Get the free weekly contract digest

The new new contracts, who’s behind them, and what they mean — delivered to your inbox every week. No credit card, unsubscribe anytime.

Weekly Digest

New new contracts, summarized for you

Straight to Inbox

No login, no app to check — it comes to you

Contract Trends

See who's moving and how much in your market

No credit card required Weekly contract digest

TearSolutions, Inc. Partners with University of Virginia for Novel Therapy Development

Nov 21, 2024•over 1 year ago

Contract Type

partnership

CharlottesvilleBiotechnologypharmaceuticals

Description

TearSolutions, Inc. has announced a partnership with the University of Virginia for the development of novel therapies to address rare corneal diseases. The partnership aims to leverage the patented Lacripep, a unique treatment modality that optimizes all three layers of the tear film while restoring corneal health and homeostasis.

Company Information

Company

TearSolutions

Location

315 Old Ivy Way

Charlottesville, Virginia, United States

About

TearSolutions Inc., a Delaware corporation based in Charlottesville, VA, has completed a successful 204-patient Phase II Proof of Concept trial for treating ocular surface disease in primary Sjögren’s Syndrome. The study showed statistically significant improvement in both signs and symptoms after two weeks using Lacripep™, a novel 19–amino acid peptide found in healthy tears but deficient in all dry eye forms. Lacripep™ restores corneal epithelial barrier function and sensory nerve activity, improving tear production and quality. Clinical benefits included reduced corneal fluorescein staining and increased tear production—key measures also used in the FDA approvals of Xiidra and Restasis.

Related People

Suggested for you

Choose your plan to reveal verified contacts

Predictive Intelligence

Strategic

ML-powered predictions for TearSolutions's next move

Learn about Strategic plan

Agreement Insights

Based on industry data

Strategic partnership established

Partnership agreements typically involve technology integration and joint go-to-market strategies

Contract momentum indicator

Companies with recent agreements are 2.3x more likely to make additional purchases within 6 months